Papers - FUJIHARA Kazuo
-
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Róisín Armstrong R, Wingerchuk DM, and the PREVENT Study Group.
Mult Scler. 28 ( 3 ) 480 - 486 2022.3
-
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Róisín Armstrong R, Wingerchuk DM, and the PREVENT Study Group.
Mult Scler. 28 ( 3 ) 480 - 486 2022.3
-
AQP4-IgG seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
1. Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk D, Green AJ, Fujihara K, Cutterj G, Aktas O, Hartung HP, Drappa J, Ratchford JN, She D, Smith M, Rees W, Cimbora D, Katz E, Cree BAC, on behalf of the N-MOmentum study investigators.
Mult Scler Relat Disord 57 103356 2022.1
-
Difference of anti-viral immunity induced by two mRNA vaccines: Implications in MS patients treated with anti-CD20-depleting therapy.
Tanaka M, Fujihara K.
Clin Exp Neuroimmunol ( 13 ) 5 - 6 2022
-
Autoantibodies in central nervous system and neuromuscular autoimmune disorders A narrative review.
Joen MY, Seok JM, Fujihara K, Kim BJ.
Precis Future Med. 6 ( 2 ) 105 - 116 2022
-
Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, aoki M, Nakashima I.
J Neurol. 2021.11
-
White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments.
Akaishi T. Misu T, Fujihara K. Nakaya N, Nakamura T, Kogure M, Hatanaka R, Itabashi F, Kanno I, Takahashi T, Kuroda H, Fujimori J, Takai Y, Nishiayama S, Kaneko K, Ishii T, Aoki M, Nakashima I, Hozawa A.
Sci Rep. 11 ( 1 ) 22357 2021.11
-
GRP78 antibodies are associated with blood-brain barrier-breakdown in anti-myelin oligodendrocyte glycoprotein antibody-associated disorder.
Shimizu F, Ogawa R, Mizukami Y, Watanabe K, Hara K, Kadono C, Takahashi T, Misu T, Takeshita Y, Sano Y, Fujisawa M, Maeda T, Nakashima I, Fujihara K, Kanda T.
Neurol Neuroimmunol Neuroinflamm. 9 ( 1 ) e1038 2021.11
-
Patient-reported burden of symptoms in neuromyelitis optica: a secondary analysis on pain and quality of life.
Fujihara K, Hattori S, Kleiter I, Levy M, Matsuda Y, Mitsutake A, Haramura M, Palace J, Yamamura T. on behalf of The Guthy-Jackson Charitable Foundation NMOSD Quality of Life Working Group.
J Neurol Sci. 428 117546 2021.9
-
MOG-antibody associated disease.
Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Dphil HA, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, De Sèze J, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, Hemmer B.
Lancet Neurol. 20 ( 9 ) 762 - 772 2021.9
-
Five-year visual outcome after optic neuritis in anti-MOG antibody-associated disease.
Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I.
Mult Scler Relat Disord Mult Scler Relat Disord. 56 103222 2021.8
-
Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, EKatz E, Cree BAC.
Neurol Neuroimmunol Neuroinflamm. 8 ( 3 ) e978 2021.5
-
Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
Takai Y, Misu T, Suzuki H, Takahashi T, Okada H, Tanaka S, Okita K, Sasou S, Watanabe M, Namatame C, Matsumoto Y, Ono H, Kaneko K, Nishiyama S, Kuroda H, Nakashima I, Lassmann H, Fujihara K, Itoyama Y, Aoki M.
Brain. 144 ( 8 ) 2401 - 2415 2021.5
-
Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder.
Akaishi T, Takahashi T, Misu T, Kaneko K, Takai Y, Nishiyama S, Ogawa R, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakashima I.
Neurology. 97 ( 1 ) e1 - e12 2021.5
-
Acute retrobulbar optic neuritis with anti-myelin oligodendrocyte glycoprotein antibody-associated disease complicated with microscopic polyangiitis: a case report.
Asano T, Saito Y, Matsuoka N, Temmoku J, Fujita Y, Hattori K, Kobayashi S, Ojima A, Takahashi T, Matsumoto H, Yashiro-Furuya M, Sato S, Kobayashi H, Watanabe H, Yano K, Sasajima T, Fujihara K, Migita K.
Medicine (Baltimore). 100 ( 15 ) e24889 2021.4
-
Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, Fujihara K; PREVENT Study Group.
Mult Scler Relat Disord. 50 ( 102849 ) 2021.2
-
Optic neuritis after ocular trauma in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Akaishi T, Himori N, Takeshita T, Fujihara K, Misu T, Takahashi T, Fujimori J, Ishii T, Aoki M, Nakazawa T, Nakashima I.
Brain Behav. 11 ( 5 ) e02083 2021.2
-
Long-term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, MD, Pittock, SJ, for the PREVENT Study Group.
Ann Neurol. 89 ( 6 ) 1088 - 1098 2021.2
-
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E.
Mult Scler. 27 ( 13 ) 2052 - 2061 2021.2
-
Progression pattern of neurological disability in reference to clinical attacks in anti-MOG antibody-associated disorders.
Akaish T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishi T, Aoki M, Fujihara K, Nakashima I.
J Neuroimmunol 31 ( 351 ) 577467 2021.2